List of Studies #
Indication
Protocol
Client
Phase
Sites
Total Target
Enrollment Time (Days)
Neurology
4
1
Epilepsy
EPY3001
J&J
III
2
40
20
2
Multiple sclerosis
BG00012
Biogen
III
6
75
Study Under Initiation
3
Parkinson’s disease
204-PD-202
Biogen
II
5
4
Vascular Dementia
E2020-A001-319
Eisai
Gastroenterology
Enrollment Ongoing 19
4
1
Hepatitis B
NV-02B-007
Novartis
III
5
100
37
2
Hepatitis
NV 022
Novartis
III
5
16
30
3
Hepatitis
NV 011
Novartis
III
5
20
475
4
Hepatitis B
AI463048
BMS
III
2
30
Enrolment ongoing
Respiratory
3
1
COPD
BY 217/M2 125
Altana
III
11
400
168
2
MDR TB
KPL/MDR/08/
Kee Pharma
II
1
10
75
3
COPD
CQAb149b2336
Novartis
1
20
Enrollment Ongoing
4
COPD
CQAB149B
Novartis
3
60
Follow up
Infectious Disease 1
Enteric Fever
2
Infectious Disease
3 4
3 GSK
IV
4
100
489
STQ105398
GSK
I
3
66
Study Under Initiation
Intra Abdominal Sepsis
3074A1-301-WW
Wyeth
III
12
200
259
Vulvovaginal Candiasis Infection
CBC 302603622467 /
KV Pharma
III
Study Under Initiation
19
Continued….